Biohit Oyj

Equities

BIOBV

FI0009005482

Office Equipment

Delayed Nasdaq Helsinki Other stock markets 12:08:09 18/07/2024 BST			5-day change	1st Jan Change
2.18 ^EUR	0.00%		+4.35%	+14.59%

06-14	Finland's Biohit Names Chief Technology Officer	MT
06-14	Biohit Oyj Announces Management Appointments, Effective August 12, 2024	CI

Biohit Oyj - Managers' Transactions - Siltala

January 18, 2022 at 01:02 pm

Person subject to the notification requirement
Name: Päivi Siltala
Position: Chief Executive Officer

Issuer: Biohit Oyj
LEI: 74370089ATTSNBXJVT29
Notification type: INITIAL NOTIFICATION
Reference number: 9324/4/6
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021A
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 20000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 20000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021B
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 20000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 20000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021C
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 20000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 20000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021D
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 20000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 20000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: I 2021E
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 20000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 20000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021A
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 25000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 25000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021B
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 25000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 25000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021C
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 25000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 25000 Volume weighted average price: 0 EUR
____________________________________________

Transaction date: 2022-01-14
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Instrument name: II 2021D
Nature of the transaction: ACCEPTANCE OF A STOCK OPTION
(X) Linked to stock option programme

Transaction details
(1): Volume: 25000 Unit price: 0 EUR
Aggregated transactions
(1): Volume: 25000 Volume weighted average price: 0 EUR

CEO Päivi Siltala, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's mission is "Innovating for Health" - we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

https://news.cision.com/biohit-oyj/r/biohit-oyj---managers--transactions---siltala,c3487978

https://mb.cision.com/Main/18502/3487978/1521705.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

© Acquiremedia - 2022

Latest news about Biohit Oyj

Finland's Biohit Names Chief Technology Officer	06-14	MT
Biohit Oyj Announces Management Appointments, Effective August 12, 2024	06-14	CI
Faron Pharmaceuticals reappoints former finance chief on interim basis	04-15	AN
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Biohit Names New Chief Commercial Officer	11-22	MT
Biohit Oyj Provides Earnings Guidance for the Period from 2024 to 2028	11-22	CI
Biohit Oyj Announces Changes in the Management Group	11-22	CI
Biohit Revises Earnings Guidance for 2023	09/08/23	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2023	09/08/23	CI
Biohit Oyj Elects Vesa Silaskivi as Chairman of the Board of Directors	15/06/23	CI
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors	14/06/23	CI
Biohit Oyj Provides Earnings Guidance for the Year 2023	15/02/23	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2022	15/02/23	CI
Biohit Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	15/02/23	CI
Biohit Oyj Announces Executive Changes	15/12/22	CI
Biohit Appoints New CFO	06/09/22	MT
Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022	06/09/22	CI
Biohit Oyj Appoints Jussi Sorvo as Member of the Management, Effective on September 7, 2022	06/09/22	CI
Finnish Biotech Biohit Appoints CFO as CEO	02/09/22	MT
Biohit Oyj Announces Executive Changes	02/09/22	CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2022	10/08/22	CI
Biohit Oyj Revises Earnings Guidance for the Year 2022	03/08/22	CI
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors	16/06/22	CI
Biohit Oyj Elects Kalle Härkönen as Board of Director	15/06/22	CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2021	16/02/22	CI

Chart Biohit Oyj

Duration

Period

Chart Biohit Oyj

Company Profile

Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Companyâs products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.

Sector

Office Equipment

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Biohit Oyj

Trading Rating

Investor Rating

ESG Refinitiv

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

2.18 EUR

Average target price

2.4 EUR

Spread / Average Target

+10.09%

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Scientific & Precision Equipment

	1st Jan change	Capi.
BIOHIT OYJ	+14.59%	36.17M
SHIMADZU CORPORATION	+9.89%	8.06B
TECAN GROUP AG	-3.15%	4.75B
JEOL LTD.	+10.90%	2.27B
ECKERT & ZIEGLER SE	+11.77%	1.05B
NINGBO YONGXIN OPTICS CO.,LTD	-38.81%	931M
PARK SYSTEMS CORP.	-2.13%	853M
FOCUSED PHOTONICS (HANGZHOU), INC.	-29.40%	692M
MLOPTIC CORP.	-58.43%	656M
PHENIX OPTICAL COMPANY LIMITED	-31.86%	605M

Scientific & Precision Equipment

Stock Market
Equities
BIOBV Stock
News Biohit Oyj
Biohit Oyj - Managers' Transactions - Siltala

Our Free Content Help you Secure and Increase the Performance of Your Investments

Secure my Investments

fermer